REPORTS

Let’s Pullulate and Expand Your Business

Global Antibody Drug Conjugates (ADCs) Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major 40 Countries or Regions

Jul 11, 2020  |  155 PAGES  |  REPORT CODE: CMM342906
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.

The Antibody Drug Conjugates (ADCs) is expected to grow from USD XX.0 million in 2018 to USD XX.0 million by 2025, at a Compound Annual Growth Rate (CAGR) of 3.1% during the forecast period. The research provides insights for the global Antibody Drug Conjugates (ADCs) market based on different Types, End-Users and Regions, and competitive landscape of these segments are analyzed in detail.

A wide range of market influence factors are taken into consideration in the analysis, and potential developing factors for different Types, End-Users and Regions are also included in the report in order to figure out the most promising development trends in the Antibody Drug Conjugates (ADCs) industry. For presenting the most potential investment fields in North America, Europe, Asia Pacific and Latin America, Middle East & Africa, the market capacity and consumption potential of more than 34 major powers are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

The Snapshot of Global Antibody Drug Conjugates (ADCs) Market Segmentations:

By Players:

  • Roche

  • Pfizer

  • Novartis

  • Genmab

  • Bayer

  • Seattle Genetics

  • Takeda Pharmaceuticals

  • AbbVie

  • AbGenomics

  • ADC Therapeutics

  • Astellas Pharma

  • Kairos Therapeutics

By Types:

  • Seattle Genetics Technology

  • ImmunoGen Technology

  • Immunomedics Technology

By End-User:

  • Hospital

  • Clinics

  • Others

By Regions:

North America

  • United States

  • Canada

  • Mexico

Europe

  • Germany

  • UK

  • France

  • Italy

  • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

  • Spain

  • Belgium

  • Poland

  • Russia

  • Turkey

  • Others

Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia and New Zealand

  • ASEAN Countries (Indonesia, Thailand, Malaysia, Singapore, Philippines, Vietnam, Others)

Latin America, Middle East & Africa

  • GCC Countries (Saudi Arabia, United Arab Emirates, Qatar, Others)

  • Brazil

  • Nigeria

  • South Africa

  • Argentina

  • Others

Table of Contents

1 Report Overview

  • 1.1 Product Definition and Scope

  • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Antibody Drug Conjugates (ADCs) Market

  • 1.3 Market Segmentation by Type

    • 1.3.1 Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Seattle Genetics Technology from 2014 to 2026

    • 1.3.2 Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of ImmunoGen Technology from 2014 to 2026

    • 1.3.3 Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Immunomedics Technology from 2014 to 2026

  • 1.4 Market Segmentation by End-Users

    • 1.4.1 Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Hospital from 2014 to 2026

    • 1.4.2 Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Clinics from 2014 to 2026

    • 1.4.3 Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Others from 2014 to 2026

  • 1.5 Market Segmentation by Regions

    • 1.5.1 North America Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.1.1 United States Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.1.2 Canada Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.1.3 Mexico Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

    • 1.5.2 Europe Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.1 Germany Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.2 UK Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.3 France Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.4 Italy Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.5 Nordic Countries Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.6 Spain Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.7 Belgium Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.8 Poland Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.9 Russia Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2.10 Turkey Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

    • 1.5.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.1 China Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.2 Japan Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.3 Australia and New Zealand Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.4 India Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.5 ASEAN Countries Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.3.6 South Korea Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

    • 1.5.4 Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.1 GCC Countries Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.2 Brazil Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.3 Nigeria Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.4 South Africa Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

      • 1.5.4.5 Argentina Antibody Drug Conjugates (ADCs) Market Size and Growth Rate from 2014 to 2026

2 Market Trends and Competitive Landscape

  • 2.1 Market Trends and Dynamics

    • 2.1.1 Market Challenges and Restraints 

    • 2.1.2 Market Opportunities and Potentials

    • 2.1.3 Mergers and Acquisitions

  • 2.2 Competitive Landscape Analysis

    • 2.2.1 Industrial Concentration Analysis

    • 2.2.2 Porter's Five Forces Analysis of the Industry

    • 2.2.3 SWOT Analysis for New Entrants

3 Segmentation of Antibody Drug Conjugates (ADCs) Market by Types

  • 3.1 Product Development Trends of Different Types

  • 3.2 Commercial Product Types of Major Vendors

  • 3.3 Competitive Landscape Analysis of Different Types

  • 3.4 Market Size of Antibody Drug Conjugates (ADCs) by Major Types

    • 3.4.1 Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Seattle Genetics Technology

    • 3.4.2 Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of ImmunoGen Technology

    • 3.4.3 Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Immunomedics Technology

4 Segmentation of Antibody Drug Conjugates (ADCs) Market by End-Users

  • 4.1 Downstream Client Analysis by End-Users

  • 4.2 Competitive Landscape Analysis of Different End-Users

  • 4.3 Market Potential Analysis of Different End-Users

  • 4.4 Market Size of Antibody Drug Conjugates (ADCs) by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Antibody Drug Conjugates (ADCs) in Hospital

    • 4.4.2 Market Size and Growth Rate of Antibody Drug Conjugates (ADCs) in Clinics

    • 4.4.3 Market Size and Growth Rate of Antibody Drug Conjugates (ADCs) in Others

5 Market Analysis by Major Regions

  • 5.1 Global Antibody Drug Conjugates (ADCs) Production Analysis by Major Regions

  • 5.2 Global Antibody Drug Conjugates (ADCs) Consumption Analysis by Major Regions

  • 5.3 Global Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis by Regions

    • 5.3.1 North America Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis 

    • 5.3.2 Europe Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis

    • 5.3.3 Asia Pacific Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis

    • 5.3.4 Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis

6 Product Commodity of Antibody Drug Conjugates (ADCs) Market in Major Countries

  • 6.1 Top 5 Export Countries in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

    • 6.1.1 Top 5 Export Countries' Export Value Analysis in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

    • 6.1.2 Top 5 Export Countries'  Export Volume Analysis in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

  • 6.2 Top 5 Import Countries in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

    • 6.2.1 Top 5 Import Countries' Import Value Analysis in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

    • 6.2.2 Top 5 Import Countries' Import Volume Analysis in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

  • 6.3 Emerging Top 3 Export Countries Analysis

  • 6.4 Emerging Top 3 Import Countries Analysis

7 North America Antibody Drug Conjugates (ADCs) Landscape Analysis

  • 7.1 North America Antibody Drug Conjugates (ADCs) Landscape Analysis by Major Types

  • 7.2 North America Antibody Drug Conjugates (ADCs) Landscape Analysis by Major End-Users

  • 7.3 North America Antibody Drug Conjugates (ADCs) Landscape Analysis by Major Countries

    • 7.3.1 United States Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 7.3.2 Canada Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 7.3.3 Mexico Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

8 Europe Antibody Drug Conjugates (ADCs) Landscape Analysis

  • 8.1 Europe Antibody Drug Conjugates (ADCs) Landscape Analysis by Major Types

  • 8.2 Europe Antibody Drug Conjugates (ADCs) Landscape Analysis by Major End-Users

  • 8.3 Europe Antibody Drug Conjugates (ADCs) Landscape Analysis by Major Countries

    • 8.3.1 Germany Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.2 UK Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.3 France Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.4 Italy Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.5 Nordic Countries Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.6 Spain Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.7 Belgium Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.8 Poland Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.9 Russia Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 8.3.10 Turkey Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

9 Asia Pacific Antibody Drug Conjugates (ADCs) Landscape Analysis

  • 9.1 Asia Pacific Antibody Drug Conjugates (ADCs) Landscape Analysis by Major Types

  • 9.2 Asia Pacific Antibody Drug Conjugates (ADCs) Landscape Analysis by Major End-Users

  • 9.3 Asia Pacific Antibody Drug Conjugates (ADCs) Landscape Analysis by Major Countries

    • 9.3.1 China Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 9.3.2 Japan Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 9.3.3 Australia and New Zealand Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 9.3.4 India Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 9.3.5 ASEAN Countries Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 9.3.6 South Korea Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

10 Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Landscape Analysis

  • 10.1 Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Landscape Analysis by Major Types

  • 10.2 Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Landscape Analysis by Major End-Users

  • 10.3 Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Landscape Analysis by Major Countries

    • 10.3.1 GCC Countries Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 10.3.2 Brazil Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 10.3.3 Nigeria Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

    • 10.3.4 South Africa Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate 

    • 10.3.5 Argentina Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate

11 Major Players Profile

  • 11.1 Roche

    • 11.1.1 Roche Company Profile and Recent Development

    • 11.1.2 Market Performance

    • 11.1.3 Product and Service Introduction

  • 11.2 Pfizer

    • 11.2.1 Pfizer Company Profile and Recent Development

    • 11.2.2 Market Performance

    • 11.2.3 Product and Service Introduction

  • 11.3 Novartis

    • 11.3.1 Novartis Company Profile and Recent Development

    • 11.3.2 Market Performance

    • 11.3.3 Product and Service Introduction

  • 11.4 Genmab

    • 11.4.1 Genmab Company Profile and Recent Development

    • 11.4.2 Market Performance

    • 11.4.3 Product and Service Introduction

  • 11.5 Bayer

    • 11.5.1 Bayer Company Profile and Recent Development

    • 11.5.2 Market Performance

    • 11.5.3 Product and Service Introduction

  • 11.6 Seattle Genetics

    • 11.6.1 Seattle Genetics Company Profile and Recent Development

    • 11.6.2 Market Performance

    • 11.6.3 Product and Service Introduction

  • 11.7 Takeda Pharmaceuticals

    • 11.7.1 Takeda Pharmaceuticals Company Profile and Recent Development

    • 11.7.2 Market Performance

    • 11.7.3 Product and Service Introduction

  • 11.8 AbbVie

    • 11.8.1 AbbVie Company Profile and Recent Development

    • 11.8.2 Market Performance

    • 11.8.3 Product and Service Introduction

  • 11.9 AbGenomics

    • 11.9.1 AbGenomics Company Profile and Recent Development

    • 11.9.2 Market Performance

    • 11.9.3 Product and Service Introduction

  • 11.10 ADC Therapeutics

    • 11.10.1 ADC Therapeutics Company Profile and Recent Development

    • 11.10.2 Market Performance

    • 11.10.3 Product and Service Introduction

  • 11.11 Astellas Pharma

    • 11.11.1 Astellas Pharma Company Profile and Recent Development

    • 11.11.2 Market Performance

    • 11.11.3 Product and Service Introduction

  • 11.12 Kairos Therapeutics

    • 11.12.1 Kairos Therapeutics Company Profile and Recent Development

    • 11.12.2 Market Performance

    • 11.12.3 Product and Service Introduction

12 Data Source and Research Methodology

The List of Tables and Figures (Totals 110 Figures and 190 Tables)

  • Figure Product Picture

  • Figure Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Seattle Genetics Technology from 2014 to 2026

  • Figure Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of ImmunoGen Technology from 2014 to 2026

  • Figure Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Immunomedics Technology from 2014 to 2026

  • Figure Market Share by Type in 2014

  • Figure Market Share by Type in 2018

  • Figure Market Share by Type in 2026

  • Figure Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Hospital from 2014 to 2026

  • Figure Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Clinics from 2014 to 2026

  • Figure Global Antibody Drug Conjugates (ADCs) Market Size and Growth Rate of Others from 2014 to 2026

  • Figure Market Share by End-User in 2014

  • Figure Market Share by End-User in 2018

  • Figure Market Share by End-User in 2026

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure United States Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Canada Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Mexico Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Germany Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure UK Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure France Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Italy Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Nordic Countries Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Spain Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Belgium Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Poland Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Russia Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Turkey Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Asia-Pacific Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure China Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Japan Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Australia and New Zealand Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure India Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure ASEAN Countries Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure South Korea Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure GCC Countries Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Brazil Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Nigeria Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure South Africa Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Argentina Antibody Drug Conjugates (ADCs) Consumption Market Size and Growth Rate from 2014 to 2026

  • Figure Development Trends and Industry Dynamics of Antibody Drug Conjugates (ADCs) Industry

  • Figure Market Challenges and Restraints

  • Figure Market Opportunities and Potentials

  • Table Mergers and Acquisition

  • Figure Market Share of TOP 3 Players in 2018

  • Figure Market Share of TOP 5 Players in 2018

  • Figure Market Share of TOP 6 Players from 2014 to 2019

  • Figure Porter's Five Forces Analysis

  • Figure New Entrant SWOT Analysis

  • Table Specifications of Different Types of Antibody Drug Conjugates (ADCs)

  • Figure Development Trends of Different Types

  • Table Commercial Products Types of Major Vendors

  • Figure Competitive Landscape Analysis of Different Types

  • Table Consumption of Antibody Drug Conjugates (ADCs) by Different Types from 2014 to 2026

  • Table Consumption Share of Antibody Drug Conjugates (ADCs) by Different Types from 2014 to 2026

  • Figure Market Size and Growth Rate of Seattle Genetics Technology

  • Figure Market Size and Growth Rate of ImmunoGen Technology

  • Figure Market Size and Growth Rate of Immunomedics Technology

  • Table Downstream Client Analysis by End-Users

  • Figure Competitive Landscape Analysis of Different End-Users

  • Table Market Potential Analysis of Different End-Users

  • Table Consumption of Antibody Drug Conjugates (ADCs) by Different End-Users from 2014 to 2026

  • Table Consumption Share of Antibody Drug Conjugates (ADCs) by Different End-Users from 2014 to 2026

  • Figure Market Size and Growth Rate of Hospital

  • Figure Market Size and Growth Rate of Clinics

  • Figure Market Size and Growth Rate of Others

  • Table Global Antibody Drug Conjugates (ADCs) Production by Major Regions

  • Table Global Antibody Drug Conjugates (ADCs) Production Share by Major Regions

  • Figure Global Antibody Drug Conjugates (ADCs) Production Share by Major Regions in 2014

  • Figure Global Antibody Drug Conjugates (ADCs) Production Share by Major Regions in 2018

  • Figure Global Antibody Drug Conjugates (ADCs) Production Share by Major Regions in 2026

  • Table Global Antibody Drug Conjugates (ADCs) Consumption by Major Regions

  • Table Global Antibody Drug Conjugates (ADCs) Consumption Share by Major Regions

  • Figure Global Antibody Drug Conjugates (ADCs) Consumption Share by Major Regions in 2014

  • Figure Global Antibody Drug Conjugates (ADCs) Consumption Share by Major Regions in 2018

  • Figure Global Antibody Drug Conjugates (ADCs) Consumption Share by Major Regions in 2026

  • Table North America Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis

  • Table Europe Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis

  • Table Asia Pacific Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis

  • Table Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Production, Import, Consumption and Export Analysis

  • Table Top 5 Export Countries' Export Value Analysis in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

  • Table Top 5 Export Countries' Export Volume Analysis in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

  • Table Top 5 Import Countries' Import Value Analysis in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

  • Table Top 5 Import Countries' Import Volume Analysis in Antibody Drug Conjugates (ADCs) market from 2014 to 2019

  • Figure Emerging Top 3 Export Countries Analysis

  • Figure Emerging Top 3 Import Countries Analysis

  • Table North America Antibody Drug Conjugates (ADCs) Consumption by Types from 2014 to 2026

  • Table North America Antibody Drug Conjugates (ADCs) Consumption Share by Types from 2014 to 2026

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2014

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2018

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2026

  • Table North America Antibody Drug Conjugates (ADCs) Consumption by End-Users from 2014 to 2026

  • Table North America Antibody Drug Conjugates (ADCs) Consumption Share by End-Users from 2014 to 2026

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2014

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2018

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2026

  • Table North America Antibody Drug Conjugates (ADCs) Consumption by Major Countries from 2014 to 2026

  • Table North America Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries from 2014 to 2026

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2014

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2018

  • Figure North America Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2026

  • Figure United States Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Canada Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Mexico Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Table Europe Antibody Drug Conjugates (ADCs) Consumption by Types from 2014 to 2026

  • Table Europe Antibody Drug Conjugates (ADCs) Consumption Share by Types from 2014 to 2026

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2014

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2018

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2026

  • Table Europe Antibody Drug Conjugates (ADCs) Consumption by End-Users from 2014 to 2026

  • Table Europe Antibody Drug Conjugates (ADCs) Consumption Share by End-Users from 2014 to 2026

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2014

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2018

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2026

  • Table Europe Antibody Drug Conjugates (ADCs) Consumption by Major Countries from 2014 to 2026

  • Table Europe Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries from 2014 to 2026

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2014

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2018

  • Figure Europe Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2026

  • Figure Germany Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure UK Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure France Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Italy Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Nordic Countries Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Belgium Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Poland Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Russia Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Turkey Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Table Asia Pacific Antibody Drug Conjugates (ADCs) Consumption by Types from 2014 to 2026

  • Table Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by Types from 2014 to 2026

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2014

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2018

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2026

  • Table Asia Pacific Antibody Drug Conjugates (ADCs) Consumption by End-Users from 2014 to 2026

  • Table Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by End-Users from 2014 to 2026

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2014

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2018

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2026

  • Table Asia Pacific Antibody Drug Conjugates (ADCs) Consumption by Major Countries from 2014 to 2026

  • Table Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries from 2014 to 2026

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2014

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2018

  • Figure Asia Pacific Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2026

  • Figure China Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Japan Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Australia and New ZealandAntibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure India Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure ASEAN Countries Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure South Korea Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Table Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption by Types from 2014 to 2026

  • Table Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by Types from 2014 to 2026

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2014

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2018

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by Types in 2026

  • Table Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption by End-Users from 2014 to 2026

  • Table Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by End-Users from 2014 to 2026

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2014

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2018

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by End-Users in 2026

  • Table Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption by Major Countries from 2014 to 2026

  • Table Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries from 2014 to 2026

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2014

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2018

  • Figure Latin America, Middle East & Africa Antibody Drug Conjugates (ADCs) Consumption Share by Major Countries in 2026

  • Figure GCC Countries Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Brazil Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Nigeria Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure South Africa Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Figure Argentina Antibody Drug Conjugates (ADCs) Market Volume and Growth Rate from 2014 to 2026

  • Table Company Profile and Development Status of Roche

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche

  • Figure Sales and Growth Rate Analysis of Roche

  • Figure Revenue and Market Share Analysis of Roche

  • Table Product and Service Introduction of Roche

  • Table Company Profile and Development Status of Pfizer

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

  • Figure Sales and Growth Rate Analysis of Pfizer

  • Figure Revenue and Market Share Analysis of Pfizer

  • Table Product and Service Introduction of Pfizer

  • Table Company Profile and Development Status of Novartis

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis

  • Figure Sales and Growth Rate Analysis of Novartis

  • Figure Revenue and Market Share Analysis of Novartis

  • Table Product and Service Introduction of Novartis

  • Table Company Profile and Development Status of Genmab

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genmab

  • Figure Sales and Growth Rate Analysis of Genmab

  • Figure Revenue and Market Share Analysis of Genmab

  • Table Product and Service Introduction of Genmab

  • Table Company Profile and Development Status of Bayer

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer

  • Figure Sales and Growth Rate Analysis of Bayer

  • Figure Revenue and Market Share Analysis of Bayer

  • Table Product and Service Introduction of Bayer

  • Table Company Profile and Development Status of Seattle Genetics

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Seattle Genetics

  • Figure Sales and Growth Rate Analysis of Seattle Genetics

  • Figure Revenue and Market Share Analysis of Seattle Genetics

  • Table Product and Service Introduction of Seattle Genetics

  • Table Company Profile and Development Status of Takeda Pharmaceuticals

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceuticals

  • Figure Sales and Growth Rate Analysis of Takeda Pharmaceuticals

  • Figure Revenue and Market Share Analysis of Takeda Pharmaceuticals

  • Table Product and Service Introduction of Takeda Pharmaceuticals

  • Table Company Profile and Development Status of AbbVie

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AbbVie

  • Figure Sales and Growth Rate Analysis of AbbVie

  • Figure Revenue and Market Share Analysis of AbbVie

  • Table Product and Service Introduction of AbbVie

  • Table Company Profile and Development Status of AbGenomics

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AbGenomics

  • Figure Sales and Growth Rate Analysis of AbGenomics

  • Figure Revenue and Market Share Analysis of AbGenomics

  • Table Product and Service Introduction of AbGenomics

  • Table Company Profile and Development Status of ADC Therapeutics

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of ADC Therapeutics

  • Figure Sales and Growth Rate Analysis of ADC Therapeutics

  • Figure Revenue and Market Share Analysis of ADC Therapeutics

  • Table Product and Service Introduction of ADC Therapeutics

  • Table Company Profile and Development Status of Astellas Pharma

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas Pharma

  • Figure Sales and Growth Rate Analysis of Astellas Pharma

  • Figure Revenue and Market Share Analysis of Astellas Pharma

  • Table Product and Service Introduction of Astellas Pharma

  • Table Company Profile and Development Status of Kairos Therapeutics

  • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kairos Therapeutics

  • Figure Sales and Growth Rate Analysis of Kairos Therapeutics

  • Figure Revenue and Market Share Analysis of Kairos Therapeutics

  • Table Product and Service Introduction of Kairos Therapeutics


Report Purchase

reports
$4480
$8960
BUY NOWClick MeBUY NOW
top